『壹』 求南京微创医学科技有限公司在江宁区的工厂地址
南京微创医学科技有限公司（南京）
公司地址：江苏省南京市高新开发区高科三路10号
邮编：210061
『贰』 南京微创医学科技有限公司 怎么样
听说还行，还是自己看看
『叁』 江苏省微纳生物医疗器械设计与制造重点实验室的发展历程
江苏省微纳生物医疗器械设计与制造重点实验室现有教授5人、副教授4人、研究生近100名，拥有各种先进的微细加工系统和分析测试系统。实验室先后完成了国家973前期预研项目、自然科学基金和863计划等数十项纵向及大量横向科研项目。获得了江苏省科技进步一等奖一项、江苏省科技进步二等奖、三等奖多项，取得了良好的社会、经济效益。
江苏省微纳生物医疗器械设计与制造重点实验室位于东南大学九龙湖校区机械楼二楼，已建成实验用房1000平米，其中建成150平米医用万级超净室和180平米恒温恒湿超净室；同时在共建单位南京微创医学科技有限公司建有实验与检测场地300平米。
实验室的建设和运行管理实行东南大学直接领导下的主任负责制。管理委员会成员由江苏省科技厅、东南大学和南京微创科学技术有限公司有关人员组成。实验室主任是最高行政和业务负责人，组织重大项目的申请与实施，制定实验室的发展规划，由东南大学聘任，任期四年。
自2003至2008年间，总共完成并承担国家863项目、国家973预研项目、国家自然科学基金重点项目、国家自然科学基金项目十余项，并与美国加州伯克利分校等国内外多家科研单位以及相关企业建立了长期合作关系。
实验室主任为易红教授，副主任为陈云飞教授与倪中华教授。
『肆』 亲人得了胆管癌，梗阻性黄疸，想用南京微创医学科技股份有限公司的胆道支架产品
国产支架可以用，只是相比进口支架在质量上还有待更大规模的使用报告，才能证明其效果。如果是自己的亲人，在当前阶段，还是优先用进口支架最踏实。
『伍』 南京生物医药谷的企业简介
南京生物医药谷已经聚集生物医药类企业142家，涵盖生物制药、化学制药、医疗器械、中医药、研发服务外包等多个门类，其对应代表企业分别有绿叶思科、药石药物、微创医学、海昌中药、金斯康科技等。这些企业自身“造血”功能强劲，盈利能力良好，其中销售过亿元企业5家，过亿元产品2个。这些各领风骚的生物医药产业集群，不仅构筑起了生物医药谷产业的新高地，也使得园区成为省内生物医药研发和孵化实力最强、数量最为集中区域之一。
『陆』 请大家帮忙翻译这段话 谢谢
Introced on behalf of the enterprise
I, on behalf of the enterprise-based R & D outsourcing
Nanjing Chuanbo Biotechnology Co., Ltd. in August 2003 incorporated in the high-tech zones, with a registered capital of 12,000,000 yuan, is a Ph.D. from abroad and domestic scientists co-founder of the biotechnology business. Chuanbo to have a biological foreign experts and overseas students as the main body and doctorate or master's degrees composition of the technical backbone of the team. The company is committed to research and development of anti-antibody protein phosphorylation, after 3 years of research and development, has succeeded in building a development of the anti-protein phosphorylation antibody technology platform, has developed 17 kinds of cell signaling pathway in the 638 kinds of anti-phosphorylation Protein antibodies, 73 of which for the first time on the international success of the development of the antibody procts, procts have been sold in the United States, Canada, Britain, France, Germany and Japan more than 20 countries. Annual output value reached 125 million. Science and Technology Development Zone Company and established a joint venture center "of the Nanjing International Antibody Engineering Research Center," the company for long-term development strategy that antibody drug research platform for international cooperation.
Second, the proction of medical equipment on behalf of the enterprise
Minimally invasive Nanjing Medical Technology Co., Ltd. specializes in interventional stent lumen, a one-time sterile digestive endoscope, and so on endoscopic biopsy forceps the annex to the research and development of procts and proction sales. Own more than 10 patents, the Ministry of Health is "100 10-year plan to" bear the unit, China is the birthplace of the one-time biopsy forceps. The company has 1500 in line with the GMP requirements of 10,000 square meters clean workshop, is currently the only shop in the clean proction of the stent business. Company sales in 2007 amounted to 100,000,000 yuan.
Third, medicine, health procts on behalf of the proction-oriented enterprises
Kang Hae Medicine Co., Ltd. Nanjing (formerly Nanking Zhenzhong Biological Engineering Co., Ltd.), the main proct is Lentinan Nanjing in a row to support the eight years of their own intellectual property rights of high-tech procts. The procts have more than 80% of the domestic market, with an annual output capacity of 650,000, the output value reached 80,000,000 yuan. The other two companies - taxol liposomes and selegiline hydrochloride in the next two years will create a proction value of 50,000,000 yuan. The company is "Lentinan freeze-dried powder", "amifostine injection", "paclitaxel liposome components" has been an international PCT patent applications and has the United States, Japan, Russia, India, Thailand, the European Union Multi-national patent applications.
High-tech Zone of bioengineering and medicine instry with the times, the instry continues to prosper and grow in 2010 and bio-medical engineering science and technology park planning area will be 5.2 square kilometers, 200 enterprises to join in annual sales 20,000,000,000 yuan . Chinese medicine and bio-technology park for a leading innovation-driven, and increase input in research funding, to foster a number of market competitiveness and self-development capacity of the backbone of the new entity; at the same time establish and improve the research and development, pilot proction technology platform. With mice research advantage of the resources of the library resources, biological targeting information technology, biomedical engineering, gene therapy technology to carry out instrialization of research work, at home and abroad to introce genetic engineering-related fields of research and development institutions to further biomedical park in Nanjing to play the "three drug "Model Base of new drugs and the role of R & D base, to build a unique national biomedical research base.
Focus on the future development of the field
① biological information technology, bio-chip technology, biomedical engineering, gene therapy, cell therapy, such as the instrialization of research. Focus on the development of bio-informatics research and development platform, biological diagnostic chips, cellular immune therapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs and vaccines and other procts.
② Chinese medicine and natural medicine quality standard certification technology; ingredient extraction, separation, purification, micro technology; active ingredients of Chinese medicine screening, the study of lead compounds, controlled-release technology of proprietary Chinese medicines, transdermal absorption of technology and targeted drug delivery technology And the development of Chinese medicine capsules, effervescent tablets, injections, pills, tablets, oral solution, and other new agents.
③ priority to the development of pharmaceutical chemical release, controlled release, targeted drug delivery technology and other modern technology. For cardiovascular disease, cancer, diabetes, autoimmune disease, kidney disease and hepatitis, multiple illnesses, development, with the introction of advanced technology at home and abroad of new drugs.
『柒』 想问下 你同学在南京微创医学科技工作从事的是什么岗位的工作啊
研发工作